Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.
Hu Y, Zhang H, Li X, Mai J, Yang L, Yan J, Li Y, Sun J, Xu W, He S, Li J, Wu M. Hu Y, et al. Among authors: mai j. Expert Opin Investig Drugs. 2022 Sep;31(9):977-985. doi: 10.1080/13543784.2021.1985464. Epub 2021 Nov 8. Expert Opin Investig Drugs. 2022. PMID: 34633260 Clinical Trial.
[Evaluation of drug-drug interactions between yimitasvir phosphate capsules with sofosbuvir tablets, omeprazole magnesium enteric-coated tablets, and rosuvastatin calcium tablets].
Mai JJ, Zhang H, Peng YY, Yang X, Mao L, Luo L, Xie HM, Zhang YJ, Li XJ, Ding YH. Mai JJ, et al. Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):838-843. doi: 10.3760/cma.j.cn501113-20200907-00503. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 33105928 Clinical Trial. Chinese.
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li C, Wu M, Zhang H, Mai J, Yang L, Ding Y, Niu J, Mao J, Wu W, Zhang D, Tang Y, Yan W. Li C, et al. Among authors: mai j. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0122021. doi: 10.1128/AAC.01220-21. Epub 2021 Jul 19. Antimicrob Agents Chemother. 2021. PMID: 34280012 Free PMC article. Clinical Trial.
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
Wu M, Li X, Yang D, Wang M, Zhang H, Li C, Mai J, Yang L, Qi Y, Yu JC, Yang X, Wang Z, Gu C, Ding Y. Wu M, et al. Among authors: mai j. BioDrugs. 2023 Jan;37(1):89-98. doi: 10.1007/s40259-022-00563-5. Epub 2022 Nov 22. BioDrugs. 2023. PMID: 36417156 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Jia H, Mai J, Wu M, Chen H, Li X, Li C, Liu J, Liu C, Hu Y, Zhu X, Jiang X, Hua B, Xia T, Liu G, Deng A, Liang B, Guo R, Lu H, Wang Z, Chen H, Zhang Z, Zhang H, Niu J, Ding Y. Jia H, et al. Among authors: mai j. BMC Med. 2023 Mar 16;21(1):98. doi: 10.1186/s12916-023-02814-w. BMC Med. 2023. PMID: 36927420 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.
Wu M, Mai J, Zhang H, Zhang G, Mao J, Tang Y, Yan W, Wu W, Hou J, Liang X, Liu Z, Ding Y, Niu J. Wu M, et al. Among authors: mai j. Virol J. 2024 Dec 20;21(1):328. doi: 10.1186/s12985-024-02584-8. Virol J. 2024. PMID: 39707469 Free PMC article. Clinical Trial.
943 results